Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
D KahnJ Gerstbrein

Abstract

We investigated the ability of In-111-capromab pendetide to separate patients who have failed radical prostatectomy into categories of those who would versus those who would not respond to salvage radiotherapy. Prostate-specific antigen (PSA) levels in 32 men with prostate cancer who had failed radical prostatectomy and had undergone a whole-body In-111-capromab pendetide scan were followed-up for 13 months (median) after salvage radiotherapy to the pelvis. A logistic regression model was used to determine whether the scan findings, as well as other clinical variables, were associated with a durable complete response (DCR), a nondurable response (NDR), or no response (NR). Sixteen of 23 (70%) men with a normal scan outside the prostatic fossa achieved a DCR after salvage radiotherapy versus two of nine (22%) who had a positive scan outside the prostate fossa and pelvis (P = .0225, Fisher's exact test). Predicted probability (95% confidence interval [CI]) that a DCR would be obtained with a normal scan was 0.88 (0.55 to 0.98); for men with a positive scan limited to the prostatic fossa it was 0.62 (0.42 to 0.79); and for men with a positive scan outside the pelvis it was 0.27 (0.09 to 0.58). No other variables before radiotherap...Continue Reading

Citations

Apr 13, 2000·Cancer Control : Journal of the Moffitt Cancer Center·M Manyak
Nov 4, 2004·BJU International·C L Amling
Apr 9, 2005·Current Opinion in Urology·Stephen A BrassellDavid G McLeod
Jun 28, 2007·BJU International·Luis Martínez-PiñeiroFelipe Cáceres
Feb 19, 2008·Expert Review of Anticancer Therapy·Michael J Manyak
Aug 29, 2000·BJU International·K E BrittonM Granowska
Nov 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shelly Bowers Hayes, Alan Pollack
Apr 29, 2006·BJU International·Nathan LawrentschukAndrew M Scott
Apr 12, 2006·Nature Clinical Practice. Urology·Neil H Bander
Apr 5, 2014·Contrast Media & Molecular Imaging·Mehdi EvazalipourNick Devoogdt
Jun 29, 2000·Medical Oncology·S N PentyalaS A Khan
May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cherry T ThomasRichard L Wahl
Feb 22, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A K LeventisK M Slawin
Jan 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D B SodeeG Bakale
Aug 4, 2011·Advances in Urology·Naveed H AkhtarScott T Tagawa
Feb 28, 2001·Expert Opinion on Investigational Drugs·E H Holmes
Jan 13, 2006·Cancer Metastasis Reviews·Jeffrey S RossNeil H Bander
Apr 8, 2006·The Journal of Urology·Juan M ProañoDouglas B Einstein
Jan 5, 2000·Seminars in Surgical Oncology·A A ElgamalG P Murphy
Sep 6, 2011·Clinical Nuclear Medicine·William J RieterLeonie L Gordon
Apr 19, 2006·Current Oncology Reports·Supriya G Mohile, Daniel P Petrylak
Mar 25, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Eleni Gourni, Gjermund Henriksen
Jun 27, 2002·Current Urology Reports·C R Pound, A W Partin
May 30, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Scott T TagawaDavid M Nanus
Oct 5, 2001·Disease-a-month : DM·J A Eastham, P T Scardino
Dec 12, 2002·Urologic Oncology·Elizabeth L Broghammer, Timothy L Ratliff
Mar 15, 2001·Urology·P H Lange
Oct 4, 2016·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Neeta Pandit-TaskarSteven M Larson
Jul 16, 2002·Cancer radiothérapie : journal de la Société française de radiothérapie oncologique·C HennequinL Boccon-Gibbod
Feb 1, 2003·Urology·Endre Z Neulander, Mark S Soloway
Feb 9, 2000·Radiologic Clinics of North America·K K Yu, R A Hawkins
Apr 25, 2006·The Urologic Clinics of North America·Michael J ManyakErik S Storm
Mar 26, 2004·Clinical Prostate Cancer·Robert A Zimmerman, Daniel J Culkin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.